J.P. Morgan discloses Kangji Medical share dealings during privatization

J.P. Morgan Securities PLC, an associate connected with the offeror, disclosed dealings in shares of Kangji Medical Holdings Limited on September 3, 2025. These transactions occurred amidst the company's privatization via a scheme of arrangement. The dealings, made for its own account, involved hedging Delta 1 products from unsolicited client-driven orders.

The disclosure shows J.P. Morgan Securities PLC sold 1,500 Kangji Medical shares for $12,993.59, with prices ranging from $8.67 to $8.68 per share. Concurrently, the firm purchased 303,500 shares for $2,635,524.46, with both the highest and lowest prices recorded at $8.68 per share.

J.P. Morgan Securities PLC is ultimately owned by JPMorgan Chase & Co. The executive received this disclosure pursuant to Rule 22 of the Hong Kong Code on Takeovers and Mergers, highlighting active market movements during Kangji Medical's privatization process.